Pricing & Access· May 22, 2026 · 12 min read
AMCP dossier evidence gaps that weaken payer review for a new specialty drug
By Ran Chen#AMCP Dossier#Formulary#Payer Review
Topic
Payer Review
Payer evidence review, P&T committee evaluation, formulary decision-making, and health technology assessment for drug coverage.
Pipeline· May 22, 2026 · 13 min read
Compendia listing gaps for oncology access before label expansion
By Ran Chen#Oncology#Market Access#Medicare Part D
Pipeline· May 22, 2026 · 13 min read
Patient-reported outcome endpoint translation from trial evidence to payer evidence
By Ran Chen#Clinical Evidence#Payer Policy#AMCP Dossier